Chargepoint: “Chargepoint is part of a very challenging group. I’ve done a lot of soul searching and, of course, a lot of research on this group. There are too many players, and there hasn’t been enough consolidation, so I’ve done this. I’m going to say avoid it.”
Prothena: “I love it. I mean, I think they have a very positive Alzheimer’s formulation and they have other things. I believe — just so we’re really clear about it and told people – That [Eli Lilly] The winner is because Lilly doesn’t have the bad job that Biogen has, wasn’t looking for big money and has a higher reputation within the brain community.”
Squarespace: “Design your own website, I don’t know. Wix, Adobe, no. I’m not into it. Direct listing. No support on Wall Street. I say no.”
Vale: “Yeah, you should be careful [of the stock’s roughly 17% dividend yield], Brazilian company, lots of … environmental problems. I don’t trust this. someone asked about [Rio Tinto] next day. I think Rio is a better company.”
Alibaba: “Long term, I want you to go. Short term, it’s obviously bouncing. Everyone can see it. President Xi is acting smart; he left, let all these stocks go up. He Will hammer you again when they move, so scale out. That’s what I recommend.”
QuantumScape: “There are detractors in this. There are big detractors in this, and I have to tell you, it worries me a lot because I want to see Volkswagen take a big stake in them and they haven’t. If they did , so I think it will really turn things around.”
Sign up now To CNBC Investment Club for following Jim Cramer’s every move in the market.
Disclosure: Cramer’s charitable trust owns shares of Eli Lilly.